OR WAIT 15 SECS
Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.
The partnership will focus on the identification and analysis of host-cell proteins in biologics.
High-throughput methods of identifying host-cell proteins in biotherapeutics will be the focus of a new partnership between SCIEX and Singapore’s Bioprocessing Technology Institute (BTI), according to a press release from SCIEX on Jan. 26, 2016.
Under the terms of the agreement, SCIEX with provide BTI with analytical mass spectrometry instruments-including the company’s TripleTOF 6600 system, Nano LC system, and proprietary software-to help BTI advance its work on the analysis of contaminating host-cell proteins in biologic drugs. In exchange, BTI will provide SCIEX with data and validation results from their studies.
Singapore’s BTI has been expanding its presence in the biologic space since early 2015. In May 2015, BTI’s Agency for Science, Technology and Research (A*STAR) division partnered with Visterra to develop a neutralizing antibody for the treatment of dengue fever. In July 2015, BTI announced a partnership with Agilent to develop new methods of glycan analysis for large-molecule protein therapeutics.